Tema Etfs LLC Has $1.09 Million Stock Holdings in AnaptysBio, Inc. $ANAB

Tema Etfs LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 105.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,560 shares of the biotechnology company’s stock after purchasing an additional 11,585 shares during the quarter. Tema Etfs LLC owned approximately 0.08% of AnaptysBio worth $1,094,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Federated Hermes Inc. boosted its holdings in shares of AnaptysBio by 2,236.6% in the 3rd quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock valued at $5,920,000 after buying an additional 185,053 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in AnaptysBio during the second quarter worth $741,000. Assenagon Asset Management S.A. raised its position in AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after acquiring an additional 822,975 shares in the last quarter. 683 Capital Management LLC raised its position in AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after acquiring an additional 304,373 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its stake in AnaptysBio by 333.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock valued at $4,446,000 after acquiring an additional 111,668 shares during the last quarter.

Insider Activity

In other news, CFO Dennis Mulroy sold 2,515 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $112,445.65. Following the completion of the sale, the chief financial officer owned 21,852 shares in the company, valued at $977,002.92. The trade was a 10.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the transaction, the insider directly owned 12,835 shares in the company, valued at $693,090. The trade was a 43.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 130,838 shares of company stock valued at $6,491,529. Company insiders own 33.50% of the company’s stock.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $57.68 on Friday. The company has a market cap of $1.66 billion, a P/E ratio of -110.92 and a beta of 0.40. The firm’s fifty day moving average price is $56.08 and its two-hundred day moving average price is $44.42. AnaptysBio, Inc. has a one year low of $15.40 and a one year high of $68.39.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The company had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. As a group, equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has authorized a stock repurchase program on Friday, March 27th that permits the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ANAB shares. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Barclays upped their target price on shares of AnaptysBio from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. Stifel Nicolaus lifted their price target on AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Wedbush upped their price objective on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.10.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.